ReviewReumatologia2016
Do we still need renal biopsy in lupus nephritis?
Review in Reumatologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Silent lupus nephritis: a pediatric center experience of baseline kidney biopsies and review of the published evidence.Pediatric nephrology (Berlin, Germany) · 2025Pooled it
- Article
- An interpretable machine learning pipeline based on transcriptomics predicts phenotypes of lupus patients.iScience · 2023Article
- Risk of bleeding-related complications after kidney biopsy in patients with systemic lupus erythematosus.Clinical rheumatology · 2023Article
- Silent Lupus Nephritis: Renal Histopathological Profile and Early Detection with Urinary Monocyte Chemotactic Protein 1.Open access rheumatology : research and reviews · 2022Article
- Linc8986 and linc0597 in plasma are novel biomarkers for systemic lupus erythematosus.Experimental and therapeutic medicine · 2021Article
- Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa.International urology and nephrology · 2021Observational
- Role of clinicopathological features for the early prediction of prognosis in lupus nephritis.Immunologic research · 2021Article
- Lupus nephritis: clinical presentations and outcomes in the 21st century.Rheumatology (Oxford, England) · 2020Review
- Risk factors for complications of percutaneous ultrasound-guided renal biopsy in children.Pediatric nephrology (Berlin, Germany) · 2020Article
- The value of repeat biopsy in lupus nephritis flares.Medicine · 2017Review
- Profiling analysis of circulating microRNA in peripheral blood of patients with class IV lupus nephritis.PloS one · 2017Article
- Low-Vacuum Scanning Electron Microscopy to Assess Histopathological Resolution of Class V Lupus Nephritis: A Case Report.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.